Qube Research & Technologies LTD Vertex Pharmaceuticals Inc Call Options Transaction History

Qube Research & Technologies LTD

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2025 Nov 14, 2025	BUY	$366.54 - $479.53 $2.57 Million - $3.36 Million	7,000 Added 60.87%	18,500 $7.25 Million
Q2 2025 Aug 14, 2025	BUY	$421.16 - $509.5 $3.96 Million - $4.79 Million	9,400 Added 447.62%	11,500 $5.12 Million
Q1 2025 May 15, 2025	SELL	$402.49 - $513.76 $9.14 Million - $11.7 Million	-22,700 Reduced 91.53%	2,100 $1.02 Million
Q4 2024 Feb 14, 2025	SELL	$396.64 - $516.74 $10 Million - $13.1 Million	-25,300 Reduced 50.5%	24,800 $9.99 Million
Q3 2024 Nov 14, 2024	BUY	$460.0 - $505.78 $22.9 Million - $25.2 Million	49,800 Added 16600.0%	50,100 $23.3 Million

Q2 2024 Aug 14, 2024	BUY	$392.81 - $485.53 $117,843 - $145,659	300 New	300 $140,000
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $3.25 Million - $3.48 Million	9,600 New	9,600 $3.34 Million

1,787

231M

1.83M

1.21M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $111B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.